One of President TrumpDonald TrumpOmar, Muslim Democrats decry Islamophobia amid death threats On The Money — Powell pivots as inflation rises Trump cheers CNN's Cuomo suspension MORE’s major proposals to lower drug prices took a step forward on Friday.
The Department of Health and Human Services (HHS) sent to the White House for review a proposal to lower certain drug prices in Medicare by linking them to the lower prices paid in other countries, an idea called the international pricing index.
There has been some speculation that the administration would never actually finalize the rule, and was simply using it as a bargaining chip to push for other drug pricing changes.
But the move to send the proposal to the White House for review, along with supportive comments from HHS Secretary Alex Azar on Friday, indicate the idea is at least moving forward.
Azar said on Fox Business on Friday that the proposal was sent to the White House that morning and said it would help close the gap between what the United States pays for drugs and what other countries do.
“We're going to end that foreign free-riding, we're going to stop having America's seniors propping up the socialist systems abroad at their expense, and we're continuing to act,” Azar said.
It is unclear how long the process of White House review will take, and whether the White House will seek to make significant changes to the proposal.
The idea, which is a sharp departure from traditional free-market GOP thinking on drug prices, has drawn opposition from some congressional Republicans.
In fact, HHS sent the proposal to the White House for review just days after Senate Finance Committee Chairman Chuck GrassleyChuck GrassleyGraham emerges as go-to ally for Biden's judicial picks Iowa Democrat drops bid to challenge Grassley after death of nephew Bipartisan senators press FBI, inspector general for changes following Nassar case MORE (R-Iowa) this week announced that he opposed the idea.
“I don't think that this administration's approach on international pricing is going to be to the benefit of the adoption of and research for modern drugs,” Grassley, who is working on his own drug pricing proposal, told reporters.
The pharmaceutical industry, a powerful force in Washington, is also fiercely opposed to the idea.